MA-BRIGHTCOVE/SUNN-STRM
16.7.2024 15:01:59 CEST | Business Wire | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today announced it has added Sunn Stream – a streaming service offering family-friendly movies, music and educational content – to its roster of media customers. Sunn Stream will rely on Brightcove’s two-time Emmy-award-winning platform to distribute its content to audiences nationwide.
Sunn Stream, currently in soft launch, is a streaming service that provides subscribers with personalized, family-friendly content, including movies, music, episodic shows, and educational videos on various topics. Using Brightcove’s reliable and scalable video technology, Sunn Stream will provide its audience with a seamless, curated, user-friendly experience across all devices.
“The streaming industry has clearly become more competitive, with providers striving to capture the attention and loyalty of more discerning audiences,” said Brightcove CEO Marc DeBevoise. “With this evolution, Sunn Stream has realized that it is essential to combine its unique content proposition targeted at a clearly-defined audience with the highest-quality video streaming and an intuitive, personalized user experience. Using our market-leading technology platform, Sunn Stream will be at the forefront of providing their customers with reliable, customized entertainment options, and will have access to best-in-class analytics to track performance.”
The popularity of independent media companies has continued to surge. As more consumers enter the fold, these entities increasingly require partners that can scale with them and ensure that customer experience remains a top priority. Sunn Stream tapped Brightcove’s industry-leading video-cloud streaming platform for its unique advantages, including unparalleled video quality, global scalability, unmatched customer support, and robust analytics.
“We’ve completely updated our Sunn Stream streaming service and app to make them easier to use so more customers can enjoy our films and shows,” said Sunn Stream Founder and President Garrett Z. Sutton. “Our curators will now handpick unexpected recommendations that our customers will love. And we’re more focused on creating an experience for the whole family that brings people together with laughter, tears, and thought-provoking moments.”
Sunn Stream joins a roster of media companies that rely on Brightcove to power their streaming capabilities, including FrightPix, The Academy of Motion Picture Arts and Sciences, Acun Medya, AMC Networks, BBC Studios, Canela Media, J.COM, MotoAmerica, REELZ, SBT TV, and SKY Mexico.
For more information, visit Brightcove.com.
About Sunn Stream
Sunn Stream is more than a streaming platform — it’s an Uncharted Entertainment and Educational Journey that takes users to bold, new worlds of cinema and television with family-friendly online content (movies, music and more) and a new Sunn Stream Film Festival (Coming Soon in 2025). As a modern-day storytelling campfire, it unites people through laughter, tears, and thought-provoking moments. This user-friendly platform delivers new narratives and experiences that appeal to multiple generations. Each month, Sunn Stream’s content curators handpick a collection of unexpected tales that ignite wonder, invite conversations and bridge hearts and minds. In addition to films and exclusive documentaries, this online platform offers quality educational content to fill voids left by public institutions such as financial education. Sunn Stream Members/ Subscribers will have unlimited access to new content that can ignite discussions with friends and family. Founded in 2022, Sunn Stream Founder/President, Bestselling Author and Entrepreneur Garrett Z. Sutton is dedicated to entertaining, educating and expanding horizons for users with new content that enhances lives. And Sunn Stream’s unique platform can be experienced online via SunnStream.com, Sunn Stream Productions App (iOS for iPads and iPhones, Apps for Android) and through Roku, Chromecast, and/or Apple TV devices. And when the credits roll, the journey is just beginning: https://sunnstream.com.
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X, Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716111027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom